AL amyloidosis: untangling new therapies
1Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL.
Hematology. American Society of Hematology. Education Program
|December 10, 2021
Summary
Systemic light chain amyloidosis (AL) involves protein misfolding and organ damage. New therapies targeting plasma cells and fibrils offer hope for managing this complex disorder.
Area of Science:
- Hematology
- Oncology
- Protein Misfolding Diseases
Background:
- Systemic light chain (AL) amyloidosis is a plasma cell dyscrasia causing organ damage via amyloid fibril deposition.
- Diagnosis is often delayed, and treatment presents challenges due to advanced organ involvement and treatment-related morbidity.
Observation:
- Current management relies on supportive care and plasma cell-directed therapies.
- Advances in multiple myeloma treatments may offer new options for AL amyloidosis.
Findings:
- Investigating novel agents is crucial for this vulnerable patient population.
- Fibril-directed therapies show promise for restoring organ function, despite initial setbacks.
Implications:
- This review explores emerging therapeutic strategies for AL amyloidosis.
- A case-based approach highlights new treatment avenues for managing this challenging condition.
Related Concept Videos
03:03Amyloid Fibrils
5.9K
5.9K
01:22Alzheimer's Disease: Treatment
288
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
288